NasdaqGS - Delayed Quote • USD
Akoya Biosciences, Inc. (AKYA)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:20 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 8 | 8 |
| Avg. Estimate | -0.29 | -0.24 | -0.83 | -0.52 |
| Low Estimate | -0.32 | -0.3 | -0.9 | -0.6 |
| High Estimate | -0.26 | -0.18 | -0.72 | -0.49 |
| Year Ago EPS | -0.49 | -0.51 | -1.43 | -0.83 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 8 |
| Avg. Estimate | 24.28M | 27.59M | 115.77M | 137.1M |
| Low Estimate | 22.55M | 26M | 115M | 134.6M |
| High Estimate | 25M | 29.3M | 116.7M | 140.39M |
| Year Ago Sales | 21.41M | 22.44M | 96.63M | 115.77M |
| Sales Growth (year/est) | 13.40% | 23.00% | 19.80% | 18.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.48 | -0.44 | -0.37 | -0.27 |
| EPS Actual | -0.49 | -0.51 | -0.26 | -0.22 |
| Difference | -0.01 | -0.07 | 0.11 | 0.05 |
| Surprise % | -2.10% | -15.90% | 29.70% | 18.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.29 | -0.24 | -0.83 | -0.52 |
| 7 Days Ago | -0.29 | -0.23 | -0.83 | -0.52 |
| 30 Days Ago | -0.28 | -0.23 | -0.84 | -0.49 |
| 60 Days Ago | -0.26 | -0.24 | -0.91 | -0.63 |
| 90 Days Ago | -0.27 | -0.24 | -0.92 | -0.65 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | -- | 1 |
Growth Estimates
| CURRENCY IN USD | AKYA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 40.80% | -- | -- | 6.50% |
| Next Qtr. | 52.90% | -- | -- | 12.00% |
| Current Year | 42.00% | -- | -- | 5.30% |
| Next Year | 37.30% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | JP Morgan: Overweight to Overweight | 3/6/2024 |
| Maintains | UBS: Buy to Buy | 3/5/2024 |
| Reiterates | Canaccord Genuity: Buy to Buy | 3/5/2024 |
| Initiated | Guggenheim: Neutral | 12/14/2023 |
| Maintains | Piper Sandler: Overweight to Overweight | 11/13/2023 |
| Maintains | Stephens & Co.: Overweight to Overweight | 11/13/2023 |
Related Tickers
OMIC Singular Genomics Systems, Inc.
0.4042
+0.90%
TRUMY Terumo Corporation
16.60
-0.12%
ANGO AngioDynamics, Inc.
5.81
+0.52%
TFX Teleflex Incorporated
206.71
0.00%
HBIO Harvard Bioscience, Inc.
3.6200
+1.69%
OSUR OraSure Technologies, Inc.
5.32
+1.14%
STVN Stevanato Group S.p.A.
27.54
+0.07%
EKSO Ekso Bionics Holdings, Inc.
1.2500
-2.34%
XRAY DENTSPLY SIRONA Inc.
30.57
+0.72%
COO The Cooper Companies, Inc.
88.84
-1.21%